OnKure Therapeutics (OKUR) Net Cash Flow (2020 - 2026)

OnKure Therapeutics (OKUR) has reported Net Cash Flow for 7 consecutive years, with -$25.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow fell 92.7% year-over-year to -$25.6 million; the trailing twelve-month figure through Jun 2026 stood at $83.1 million (up 28.4% YoY), and the FY2025 full-year result was -$51.7 million, down 163.93% from the prior year.
• Net Cash Flow fell to -$25.6 million in Q2 2026 per OKUR's latest filing, from $133.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $133.1 million in Q1 2026 and bottomed at -$56.1 million in Q3 2022.
• Historically, Net Cash Flow has averaged $2.8 million across 5 years, with a median of -$10.7 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Net Cash Flow tumbled 2313.09% in 2022, then jumped 1043.66% in 2026.
• Over 5 years, Net Cash Flow stood at -$42.2 million in 2022, then soared by 162.84% to $26.5 million in 2023, then surged by 287.6% to $102.8 million in 2024, then sank by 110.97% to -$11.3 million in 2025, then plunged by 126.97% to -$25.6 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$25.6 million, $133.1 million, and -$11.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.